type 1 diabetes and glp 1 In patients with residual ß-cell function, GLP-1 treatment Improved Heart and Kidney Outcomes

GLP-1 medications restore what the body is not doing on its own

& Kahn C

She emphasized restricting the compounding of these peptides (even where no FDA-approved alternative exists) may leave patients without regulated access, potentially driving them toward unregulated, gray-market sources

A 2013 study in Bangladesh looked at people exposed to different levels of arsenic in their drinking water

These factors support continued research interest despite the disappointing oral efficacy results

The approval is backed by results from the Phase IIb/III QUASAR study, in which participants given 200 mg of Tremfya every four weeks saw clinical remission at 44 weeks, compared with 19% in the placebo group